Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Study Information
Alliance Study ID: NCCTG-N0432
NCT Study ID (ClinicalTrials.gov): NCT00088998
Disease or Cancer Type: Breast Cancer
Alliance Study Chair: Edith A. Perez, MD
Status: COMPLETED
Study Description
RATIONALE: Drugs used in chemotherapy, such as docetaxel and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Bevacizumab may also stop the growth of tumor cells by stopping blood flow to the tumor. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving docetaxel and capecitabine together with bevacizumab works in treating patients with metastatic breast cancer.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information